MedTech Atlas
Back to medical device regulatory guideAll countries
AmericasENPublic regulatory overview

Colombia

Market Overview Population: Approximately 52 million (2024), one of the largest economies in the Andean region Healthcare system: The SGSSS (Sistema General de Seguridad Social en...

Updated: 2026-05-04

You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.

Sign in / register for full country report
Reference approval strategy

FDA / CE / MDSAP / NMPA benefits for this market

These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.

US FDA

510(k) / De Novo / PMAStrong benefit

FDA evidence can materially improve review confidence and may support verification, abridged, or reliance-style pathways.

Likely benefit
  • Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
  • May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
  • Does not remove local holder, language, labeling, fee, import, or post-market obligations.
View topic

EU CE

MDR / IVDRStrong benefit

CE documentation is highly reusable and may support reference, reliance, or overseas conformity assessment routes.

Likely benefit
  • Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
  • Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
  • Does not replace local registration or local representative responsibilities outside the CE-recognized route.
View topic

MDSAP

Single QMS auditIndirect QMS signal

MDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.

Likely benefit
  • Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
  • Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
  • Does not authorize product sale and does not replace safety, performance, or clinical evidence.
View topic

China NMPA

China registration / filingSupportive evidence

NMPA approval can serve as prior-market evidence and a commercial credibility signal, especially for China-made products.

Likely benefit
  • Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
  • Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
  • Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
View topic

AI Citation Summary

  • Country: Colombia
  • Product line: Medical devices
  • Regulator / source: Regulatory maturity: Moderate — the INVIMA framework is generally sound and references EU/GHTF principles; it has been continuously improved in recent years. The SIRIS online system has improved transparency. However, reviewer resources are limited and review timelines for high-risk devices are lengthy
  • Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
  • Typical timeline: Regulatory maturity: Moderate — the INVIMA framework is generally sound and references EU/GHTF principles; it has been continuously improved in recent years. The SIRIS online system has improved transparency. However, reviewer resources are limited and review timelines for high-risk devices are lengthy
  • Key fees: Market characteristics: The medical device market is valued at approximately USD 1.5–2 billion per year, with a high import dependency (approximately 85%). The market is concentrated in Bogotá, Medellín, and Cali. Government procurement (including EPSs and public hospitals) accounts for approximately 60% of the market. Both medicines and devices are regulated by INVIMA under a unified framework
  • Local requirement: Colombia medical-device entry should be separated into INVIMA regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.
  • Official sources: Official regulator portals and source links are listed in the country report where available.
  • Last verified: 2026-05-04
  • Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
  • Preferred citation: MedTech Atlas

Market Overview

  • Population: Approximately 52 million (2024), one of the largest economies in the Andean region
  • Healthcare system: The SGSSS (Sistema General de Seguridad Social en Salud) universal health insurance framework operates through a two-tier structure of EPSs (Entidades Promotoras de Salud, insurance entities) and IPSs (Instituciones Prestadoras de Servicios, service delivery institutions); the public contributory/subsidized regime and the private contributory regime operate in parallel
  • Market characteristics: The medical device market is valued at approximately USD 1.5–2 billion per year, with a high import dependency (approximately 85%). The market is concentrated in Bogotá, Medellín, and Cali. Government procurement (including EPSs and public hospitals) accounts for approximately 60% of the market. Both medicines and devices are regulated by INVIMA under a unified framework
  • Regulatory maturity: Moderate — the INVIMA framework is generally sound and references EU/GHTF principles; it has been continuously improved in recent years. The SIRIS online system has improved transparency. However, reviewer resources are limited and review timelines for high-risk devices are lengthy

Market-Entry Logic

Colombia medical-device entry should be separated into INVIMA regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.

Entry layer Key question Practical view
Regulatory route Which product category, risk class, application type, reliance route, or special pathway applies? Confirm the pathway before translating the dossier; route choice drives evidence, timing, fees, inspections, labelling, and change-control obligations
Local execution Who holds the registration, imports, answers regulator questions, manages safety reporting, and controls renewals or variations? Contract structure matters because local agents, sponsors, distributors, or licence holders can control practical market access even when the foreign manufacturer owns the product
Evidence and economics What clinical, quality, performance, HTA, pricing, and budget-impact evidence is needed? Registration evidence and payer evidence should be planned together; otherwise approval may be achieved without reimbursement, tender access, or hospital adoption
Channel access Which payer, hospital, distributor, retail, tender, or private-care channel will create volume? Start with the channel that matches product value and service burden; premium products often need reference sites before broad tender or retail expansion

Main Players and Channel Map

Type Representative players Market meaning
Regulator / review INVIMA Determines approval route, technical evidence, inspections, labelling, post-market duties, renewals, and variations
Payment / procurement ADRES, EPS insurers, IETS, public procurement and private providers Determines reimbursement, tender economics, price ceilings, purchasing lists, and patient affordability
Companies / channels local importers, distributors, Fundación Santa Fe, Clínica del Country, EPS-linked providers and multinational medtech companies Shows the competitive set, partner universe, distribution power, hospital access points, and local execution benchmarks
End users / buyers Public hospitals, private hospital groups, specialist centers, laboratories, pharmacies, insurers, and regional distributors Determine adoption, tender volume, reference cases, service expectations, and receivables risk
  1. Approval and access are increasingly separate: Technical approval does not guarantee reimbursement, procurement listing, physician adoption, or patient affordability.
  2. Local execution quality is a major differentiator: Strong local regulatory, medical, market-access, distribution, and service teams reduce deficiency, launch, and lifecycle risk.
  3. Evidence expectations are rising: Payers and hospitals increasingly ask for comparative clinical value, real-world evidence, budget impact, and operational service data.
  4. Pricing pressure is structural: INVIMA timelines, EPS liquidity risk, price controls, distributor-held registrations, private provider networks and Andean regional access are reshaping launch sequencing and product economics.
  5. Partner control should be managed early: Contracts should protect dossier access, registration ownership, renewal obligations, safety reporting, inventory, and transition rights.

Regulatory Authority

  • Primary authority: INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos), under the Ministerio de Salud y Protección Social
  • Official portal: https://www.invima.gov.co; electronic filing system: SIRIS (https://siris.invima.gov.co)
  • Key regulations:
    • Decreto 4725/2005 (core regulation on medical device and IVD registration)
    • Resolución 4816/2008 (vigilance/pharmacovigilance system)
    • Resolución 2013 series (classification and technical requirements updates)
    • Decreto 1071/2015 (simplified administrative procedures)
    • Resolución 3100/2019 (healthcare technology conditions)
    • Ongoing Circulares Técnicas (technical circulars)

Device Classification

Local Classification Risk Level EU/FDA Equivalent Description
Clase I Low risk EU Class I / FDA Class I Self-certification; INVIMA notification; simplest process
Clase IIA Low-moderate risk EU Class IIa / FDA Class II Registro Sanitario; standard review
Clase IIB Moderate-high risk EU Class IIb / FDA Class II-III Registro Sanitario; more stringent review
Clase III High risk EU Class III / FDA Class III Registro Sanitario; most stringent; complete clinical evidence required
Clase IV Highest risk EU Class III (most stringent) / FDA Class III PMA Very limited category (e.g., certain long-term implants); most stringent review

Note: Decreto 4725/2005 sets out the classification rules. In practice, the boundary between Clase I and Clase IIA can be ambiguous; classification should be confirmed in advance. IVDs are classified separately according to a specific list.

Registration Pathways

During the limited-time free period, sign in or register to view the complete medical device country report.